JNJ-81241459 50mg clinical trials

A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis

This study is looking into a new medicine, JNJ-81241459, for people with moderate to severe plaque psoriasis. We want to see how well different doses work to clear up skin patches and if it's safe. It's a key step in developing new treatments.